¿Por qué tenemos cosquillas?
En este Short nos preguntamos por qué razón biológica tenemos cosquillas los humanos. …
Uncategorized
NYSE TO SUSPEND TRADING IMMEDIATELY IN LANNETT COMPANY, INC. (LCI) AND COMMENCE DELISTING PROCEEDINGS
Lannett Company, Inc. (LCI) (“Lannett” or “the Company”) today announced that it received a written notice from the New York Stock Exchange (“NYSE”) dated April 19, 2023, notifying the Company that the NYSE will commence proceedings to delist the Company’s common stock from the NYSE.
Haemonetics Publishes Inaugural Corporate Responsibility Report
Haemonetics Corporation today announced the release of its 2022 Corporate Responsibility Report.
Haemonetics Publishes Inaugural Corporate Responsibility Report Read More »
Invitation to a Presentation of the Results from Promore Pharma’s Clinical Trial PHSU05
Promore Pharma In the light of the publication of the results from the clinical trial PHSU05, Promore Pharma AB invites to a webcast on Friday 21 April kl 10.00
Invitation to a Presentation of the Results from Promore Pharma’s Clinical Trial PHSU05 Read More »
Immunovia to participate in National Pancreas Foundation Webinar on Biomarkers and Liquid Biopsy for Early Detection of Pancreatic Cancer
Immunovia announced it will participate in a webinar titled “Biomarkers and Liquid Biopsy for Early Detection of Pancreatic Cancer” hosted by the National Pancreas Foundation on April 26, 2023, at 7:00 pm ET.
Promore Pharma Reports Outcome from Clinical Phase II Study with Ensereptide
Promore Pharma AB announces that the results from the company’s Phase II study PHSU05 with ensereptide in prevention of skin scarring have been concluded.
Promore Pharma Reports Outcome from Clinical Phase II Study with Ensereptide Read More »
Hansa Biopharma interim report January-March 2023
Hansa Biopharma, the pioneer in immunomodulatory enzyme technology for rare IgG mediated diseases, announced its business update and interim report for January to March 2023.
Hansa Biopharma interim report January-March 2023 Read More »
IRLAB Announces New Date for Publication of the Annual Report
IRLAB Therapeutics AB, a company that discovers and develops new treatments for Parkinson’s disease, announced that the company’s annual report for 2022 will be published during the week commencing April 24.
IRLAB Announces New Date for Publication of the Annual Report Read More »
BioInvent Announces a Fourth Complete Response in Phase 1/2 Trial with BI-1206 in Non-Hodgkin’s Lymphoma
BioInvent International AB announces that a fourth complete response has been observed in the 100 mg dose expansion cohort in the IV arm of the Phase 1/2 trial of its lead drug candidate BI-1206, the novel anti-FcgRIIB antibody, in combination with rituximab in non-Hodgkin’s lymphoma.
Innovent Announces Overall Survival Results of Phase 2 Study of Pemazyre® (pemigatinib) in Chinese Patients with Advanced Cholangiocarcinoma Presented at AACR Annual Meeting 2023
Innovent Biologics, Inc., announced that the overall survival results of the Phase 2 study of pemigatinib in Chinese patients with advanced cholangiocarcinoma were presented at the American Association for Cancer Research Annual Meeting 2023.